Rezolute, Inc.
NASDAQ:RZLTBiotechnology
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
Volume 2.93M
Average 2.03M
RZLT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Rezolute, Inc.NASDAQ: RZLT
EBITDA · Q3 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q3 FY2026 EBITDA was -$16.16M, compared with -$18.91M a year earlier. Trailing-twelve-month EBITDA was -$81.45M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Jun 2026, a step up from the -8.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.16M+29.0% QoQ
- Last fiscal yearJun 2025
- -$74.38M-8.7% YoY
- LTMMar 2026
- -$81.45M-11.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +14.5% | +100.0% | +85.5 pp |
| 1 year | -8.7% | +100.0% | +108.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (74.38M) USD
- Year-over-year change
- -8.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | (74.38M) | -8.7% |
| FY2024 | 2024-06-30 | (68.42M) | -32.2% |
| FY2023 | 2023-06-30 | (51.76M) | -31.9% |
| FY2022 | 2022-06-30 | (39.24M) | -91.3% |
| FY2021 | 2021-06-30 | (20.51M) | — |
EBITDA vs competitors
How RZLT compares with its peers on the latest reported figures
- RZLT's LTM Mar 2026 EBITDA of -$81.45M is the 4th highest of the 5 companies compared; the peer median is $5.71M.
- Its year-over-year change of -11.6% is the 4th highest of 5, against a peer median of +63.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $140.47M | +332.9% | — | 114.9% | |
| LTM Mar 2026 | $39.48M | +82.4% | -1.9% | 10.7% | |
| LTM Mar 2026 | -$28.06M | +44.2% | — | 3270.4% | |
| LTM Mar 2026 | -$81.45M | -11.6% | — | — | |
| LTM Mar 2026 | -$503.35M | -11.9% | — | 75.2% | |
| Peer median (excluding RZLT) | $5.71M | +63.3% | -1.9% | 95.0% | |
Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13K | 0 | 0 | 0 | 0 |
| Gross Profit | (13K) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 14.99M | 32.49M | 43.81M | 55.74M | 61.53M |
| Selling, General & Admin | 7.91M | 9.36M | 12.18M | 14.68M | 18.37M |
| Operating Expenses | 22.88M | 41.84M | 55.99M | 70.42M | 79.89M |
| Depreciation & Amortization | 13K | 13K | 30K | 36K | 31K |
| EBITDA | (20.51M) | (39.24M) | (51.76M) | (68.42M) | (74.38M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (22.89M) | (41.84M) | (55.99M) | (70.42M) | (79.89M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 63K | 80K | 4.21M | 4.87M | 5.48M |
| Interest Expense | 375K | 1.81M | 0 | 0 | 0 |
| Other Income / Expenses | 1.99M | 783K | 4.2M | 1.96M | 5.48M |
| Income Before Tax | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (20.9M) | (41.06M) | (51.79M) | (68.46M) | (74.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.72) | (2.26) | (1.01) | (1.33) | (0.98) |
| EPS (Diluted) | (2.72) | (2.32) | (1.01) | (1.33) | (0.98) |
| Weighted Avg Shares | 7.67M | 18.2M | 51.19M | 51.47M | 76M |
| Weighted Avg Shares (Diluted) | 7.67M | 19.49M | 51.19M | 51.47M | 76M |
Rezolute, Inc.
NASDAQ:RZLT
Intrinsic Alpha fair value
Locked
Current Price
$4.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.